Human skin microbiota-friendly lysostaphin

Growing antibiotic resistance of bacteria is a burning problem human and veterinary medicine. Expansion introduction novel microbicidal therapeutics highly desirable. However, treatment disturbs the balance physiological microbiota by changing its qualitative and/or quantitative composition, resulting in number adverse effects that include secondary infections. Although such dysbiosis may be reversed with probiotics, more attractive alternative use antibiotics target only pathogens, while sparing commensals. Here, we describe lysostaphin LSp222, an enzyme produced naturally Staphylococcus pseudintermedius 222. LSp222 effective against S. aureus, including multi-drug resistant strains. Importantly, inhibitory concentration for epidermidis, predominant commensal healthy skin, at least two orders magnitude higher compared to aureus. Such significant therapeutic window makes microbiota-friendly antibacterial agent potential application aureus-driven skin